Pacritinib bests BAT, doesn’t seem to affect survival

The hazard ratios for death were 1.18 in the once-daily pacritinib arm and 0.68 in the twice-daily pacritinib arm.

Safety

Dr Mascarenhas said pacritinib had “a generally manageable safety profile.”

Common adverse events—in the once daily, twice daily, and BAT arms, respectively—included:

• Diarrhea­—67%, 48%, and 15%
• Nausea—38%, 32%, and 11%
• Thrombocytopenia—33%, 34%, and 23%
• Anemia—28%, 24%, and 15%
• Vomiting—21%, 19%, and 5%
• Fatigue—17%, 17%, and 16%
• Peripheral edema—13%, 2%, and 15%
• Dizziness—14%, 15%, and 5%
• Abdominal pain—19%, 9%, and 19%
• Pyrexia—11%, 15%, and 3%.

Grade 3/4 events—in the once daily, twice daily, and BAT arms, respectively­—included:

• Thrombocytopenia—31%, 32%, and 18%
• Anemia—27%, 22%, and 14%
• Neutropenia—9%, 7%, and 5%
• Pneumonia—4%, 7%, and 3%
• Fatigue—7%, 3%, and 5%
• Diarrhea—5%, 4%, and 0%
• Epistaxis—2%, 5%, and 1%.

Serious adverse events—in the once daily, twice daily, and BAT arms, respectively—included:

• Anemia—5%, 8%, and 3%
• Thrombocytopenia—2%, 6%, and 2%
• Pneumonia—5%, 6%, and 4%
• Acute renal failure—5%, 2%, and 2%
• Congestive heart failure—1%, 4%, and 2%
• Atrial fibrillation—3%, 0%, and 3%
• Cardiac arrest—2%, 0%, and 0%
• Epistaxis—2%, 2%, and 1%
• Subdural hematoma—2%, 0%, and 0%.